Physician profile
John J Treece
NPI 1023603131
$4,290.45
in general payments reported to CMS, 2019-2025
30 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.93 · 2023: $896 · 2024: $1,595 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,244.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $742.13 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $522.30 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $353.16 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $293.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $278.51 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $242.53 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $201.74 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $195.44 | 2024-2025 | Auvelity |
| Amgen INC. | $149.20 | 2022-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $147.96 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $137.55 | 2022-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $136.22 | 2024-2025 | Rexulti |
| Exact Sciences Corporation | $122.17 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boston Scientific Corporation | $103.04 | 2023-2025 | Watchman Access System, General - Female Sui |
| Astellas Pharma US INC | $100.79 | 2023-2025 | Veozah |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $55.06 | 2023-2025 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $55.01 | 2024-2025 | Voquezna |
| Corium, LLC | $54.47 | 2023 | Adlarity |
| Daiichi Sankyo INC. | $54.28 | 2024-2025 | Injectafer |
| Dynavax Technologies Corporation | $51.84 | 2023-2025 | Heplisav-B |
| Radius Health, INC. | $49.82 | 2023-2024 | Tymlos |
| Novartis Pharmaceuticals Corporation | $44.90 | 2024 | |
| Inspire Medical Systems, INC. | $34.80 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $34.66 | 2025 | Caplyta |
| Corcept Therapeutics | $34.52 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $31.78 | 2023 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.46 | 2023 | Tradjenta |
| Idorsia Pharmaceuticals US INC | $16.91 | 2024 | Quviviq |
| Acella Pharmaceuticals, LLC | $15.26 | 2025 | NP Thyroid 60 |
| Ardelyx, INC. | $13.91 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Treece listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.